Related Experiment Video

Updated: Dec 14, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.7K

Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective

Azita Hajhossein Talasaz1,2, Hessam Kakavand3, Benjamin Van Tassell4,5

  • 1Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.

Cardiovascular Drugs and Therapy
|July 17, 2020
PubMed

Insights

This review examines pharmacotherapies for cardiovascular complications of COVID-19, including heart failure and arrhythmias. It also discusses potential drug interactions for treating SARS-CoV-2 infection.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is a global pandemic.
  • Patients with cardiovascular disease face higher COVID-19 mortality and morbidity risks.
  • COVID-19 can precipitate acute cardiovascular events even in healthy individuals.

Purpose of the Study:

  • To review current evidence on pharmacotherapies for COVID-19-related cardiovascular complications.
  • To explore potential drug interactions between COVID-19 treatments and cardiovascular medications.

Main Methods:

  • Literature review of recent evidence on COVID-19 and cardiovascular complications.
  • Analysis of pharmacotherapies for conditions such as acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism.
  • Examination of drug-drug interactions.

Main Results:

  • Several medications are used globally for SARS-CoV-2 infection, including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents.
  • Specific cardiovascular complications of COVID-19 include acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism.
  • Potential interactions exist between COVID-19 treatments and cardiovascular medications.

Conclusions:

  • Effective pharmacotherapies are needed for cardiovascular complications arising from COVID-19.
  • Understanding drug interactions is crucial for managing patients with both COVID-19 and cardiovascular conditions.
  • Further research is warranted to optimize treatment strategies for cardiovascular manifestations of SARS-CoV-2 infection.

Keywords:
COVID-19CardiovascularDrug–drug interactionsPharmacotherapySARS-Cov2Venous thromboembolism

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.5K

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.8K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
353
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
134
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
773
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
201
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
164